Last reviewed · How we verify
US-Ocrevus
US-Ocrevus is a monoclonal antibody that targets CD20 on B cells, depleting them to reduce autoimmune-mediated inflammation.
US-Ocrevus is a monoclonal antibody that targets CD20 on B cells, depleting them to reduce autoimmune-mediated inflammation. Used for Multiple sclerosis (relapsing and primary progressive forms), B-cell non-Hodgkin lymphoma.
At a glance
| Generic name | US-Ocrevus |
|---|---|
| Also known as | Ocrelizumab |
| Sponsor | Celltrion |
| Drug class | Monoclonal antibody (CD20 inhibitor) |
| Target | CD20 |
| Modality | Biologic |
| Therapeutic area | Immunology / Oncology |
| Phase | Phase 3 |
Mechanism of action
US-Ocrevus (ocrelizumab biosimilar candidate by Celltrion) binds to CD20 antigen expressed on B lymphocytes, leading to B cell depletion through antibody-dependent cellular cytotoxicity and direct apoptosis. This mechanism reduces pathogenic B cell-mediated autoimmune responses in conditions like multiple sclerosis and certain B-cell malignancies.
Approved indications
- Multiple sclerosis (relapsing and primary progressive forms)
- B-cell non-Hodgkin lymphoma
Common side effects
- Infusion reactions
- Infections (including serious infections)
- Immunosuppression
- Headache
Key clinical trials
- People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
- Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) (PHASE3)
- Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- US-Ocrevus CI brief — competitive landscape report
- US-Ocrevus updates RSS · CI watch RSS
- Celltrion portfolio CI